Uzbekistan’s pharmaceutical industry is rapidly growing, driven by strong government support, large-scale investments, and rising demand. The industry's foreign trade turnover reached $2.6 billion in 2024, with pharmaceutical exports increasing by 50% annually.

Five specialized pharmaceutical free economic zones (FEZs) have been established, offering up to 10 years of tax exemptions, duty-free import of raw materials, and low operating costs. The average monthly salary ranges between $300–400, and resource costs are among the lowest in the region.

A key infrastructure project is the Tashkent Pharma Park — a 190-hectare cluster with $1.4 billion in investments, integrating production facilities, R&D centers, and educational institutions.

With over 2,600 registered products and 56 GMP-certified companies, Uzbekistan is emerging as Central Asia’s leading pharmaceutical hub, offering investors a rapidly developing ecosystem and an expanding market.

Uzbekistan offers competitive infrastructure costs, making it an attractive location for manufacturing investments. Key costs include:

- Gas: 12 cents per m³

- Electricity: 7 cents per kWh

- Water: 20 cents per m³

GSP+ agreement allows to export to EU at reduced or zero tariff for 6 200 products. CIS Free Trade Agreement creates more integrated and open market with CIS countries.

Investors in Free Economic Zones (FEZs) can benefit from tax exemptions on land, property, water, and corporate income tax (CIT).

3 years: for investments between 0.3 - 3 million USD

5 years: for investments between 3 - 5 million USD

7 years: for investments between 5 - 10 million USD

10 years: for investments over 10 million USD